ArticleCurrent treatment options in oncology2012
Treatment of leptomeningeal spread of NSCLC: a continuing challenge.
Article in Current treatment options in oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 29 citations in OpenAlex.
- The evolving landscape of leptomeningeal metastases from NSCLC: an international, contemporary, multicenter cohort study.Annals of oncology : official journal of the European Society for Medical Oncology · 2026Article
- MRI-based morphological and spatial characteristics of leptomeningeal metastasis: prognostic value in non-small cell lung cancer.Frontiers in oncology · 2026Article
- Review
- Case report: Cerebrospinal fluid-derived circulating tumor DNA diagnoses and guides the treatment of a lung adenocarcinoma case with leptomeningeal metastasis.Frontiers in oncology · 2022Article
- The Presence of Genomic Instability in Cerebrospinal Fluid in Patients with Meningeal Metastasis.Cancer management and research · 2021Article
- Article
- Recurrently Mutated Genes Differ between Leptomeningeal and Solid Lung Cancer Brain Metastases.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2018Article
- Medical Treatment Options for Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Suffering from Brain Metastases and/or Leptomeningeal Disease.Targeted oncology · 2018Review
- Preclinical Modeling and Therapeutic Avenues for Cancer Metastasis to the Central Nervous System.Frontiers in oncology · 2017Review
- Detection value of tumor cells in cerebrospinal fluid in the diagnosis of meningeal metastasis from lung cancer by immuno-FISH technology.Oncology letters · 2016Article
- Intrathecal chemotherapy as a treatment for leptomeningeal metastasis of non-small cell lung cancer: A pooled analysis.Oncology letters · 2016Article
- Tumor DNA in cerebral spinal fluid reflects clinical course in a patient with melanoma leptomeningeal brain metastases.Journal of neuro-oncology · 2016Article
- Detected EGFR mutation in cerebrospinal fluid of lung adenocarcinoma patients with meningeal metastasis.Open medicine (Warsaw, Poland) · 2016Article
- Diagnostic value of circulating tumor cells in cerebrospinal fluid.Open medicine (Warsaw, Poland) · 2016Article
- Novel method for the detection and quantification of malignant cells in the CSF of patients with leptomeningeal metastasis of lung cancer.Oncology letters · 2016Article
- [Research progress of lung cancer with leptomeningeal metastasis].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2014Review
- Acquired resistance to TKIs in solid tumours: learning from lung cancer.Nature reviews. Clinical oncology · 2014Review
- Neuro-ophthalmologic complications of neoplastic leptomeningeal disease.Current neurology and neuroscience reports · 2013Review
- Treatment of Leptomeningeal Carcinomatosis in a Patient with Metastatic Pancreatic Cancer: A Case Report and Review of the Literature.Case reports in oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
opinion statementLeptomeningeal metastasis is a serious and frequently fatal complication of non-small cell lung cancer. Curative treatment remains elusive, but careful use of radiation, systemic chemotherapy, intrathecal chemotherapy, and symptoms management can greatly improve quality of life and survival. For most patients, we recommend a combination of skull-based radiation with focal radiation to any symptomatic spinal segments followed by systemic chemotherapy. For patients with EGFR mutations, erlotinib may be used as first-line therapy in a daily or high-dose regimen. Pemetrexed has promise for use in patients with brain and leptomeningeal metastases. Patients with multiple comorbidities or low performance status may tolerate intrathecal therapy better than systemic chemotherapy. The most commonly used intrathecal chemotherapies are methotrexate and liposomal cytarabine, although newer agents, such as topotecan and mafosfamide, may be more effective. Elevated intracranial pressure, which causes headaches, vertigo, nausea, and vomiting, should be treated with dexamethasone and acetazolamide. In select patients, cerebrospinal fluid shunting may be considered. The use of antidepressants, central nervous system stimulants, benzodiazepines, antiemetics, and pain medications can increase quality of life in patients with leptomeningeal metastases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.